Markers of Collagen Formation and Degradation Reflect Renal Function and Predict Adverse Outcomes in Patients With Type 1 Diabetes.


Journal

Diabetes care
ISSN: 1935-5548
Titre abrégé: Diabetes Care
Pays: United States
ID NLM: 7805975

Informations de publication

Date de publication:
09 2019
Historique:
received: 19 12 2018
accepted: 13 06 2019
pubmed: 3 7 2019
medline: 19 5 2020
entrez: 3 7 2019
Statut: ppublish

Résumé

Patients with type 1 diabetes (T1D) have a higher risk of developing chronic kidney disease, cardiovascular events (CVEs), and mortality than the general population. We hypothesized that two previously published biomarkers, namely PRO-C6, a biomarker of collagen type VI formation, and C3M, a biomarker of collagen type III degradation, may be associated with impaired renal function and have prognostic value for adverse renal, CVE, and mortality in patients with T1D. PRO-C6 and C3M in serum (sPRO-C6, sC3M) and urine (uPRO-C6, uC3M) were measured by ELISA in 663 patients with T1D ranging from normoalbuminuric to macroalbuminuric. Association of the biomarkers with mortality, CVEs, heart failure, decline in estimated glomerular filtration rate (eGFR) ≥30%, and end-stage renal disease (ESRD) were tested in Cox proportional hazards models after log High levels of sPRO-C6 were independently associated with a higher risk of all-cause mortality (HR 2.26 [95% CI 1.31-3.87], In patients with T1D, higher sPRO-C6 was an independent predictor of both decline in eGFR and development of ESRD and of all-cause mortality. Higher uPRO-C6 was also associated with a lower risk of decline in eGFR.

Identifiants

pubmed: 31262950
pii: dc18-2599
doi: 10.2337/dc18-2599
doi:

Substances chimiques

Biomarkers 0
Collagen Type III 0
Collagen Type VI 0
Procollagen 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1760-1768

Informations de copyright

© 2019 by the American Diabetes Association.

Auteurs

Sascha Pilemann-Lyberg (S)

Steno Diabetes Center Copenhagen, Gentofte, Denmark sply@novonordisk.com.

Tine Willum Hansen (TW)

Steno Diabetes Center Copenhagen, Gentofte, Denmark.

Nete Tofte (N)

Steno Diabetes Center Copenhagen, Gentofte, Denmark.

Signe Abitz Winther (SA)

Steno Diabetes Center Copenhagen, Gentofte, Denmark.

Signe Holm Nielsen (S)

Nordic Bioscience, Herlev, Denmark.
Technical University of Denmark, Lyngby, Denmark.

Simone Theilade (S)

Steno Diabetes Center Copenhagen, Gentofte, Denmark.

Morten Asser Karsdal (MA)

Nordic Bioscience, Herlev, Denmark.

Federica Genovese (F)

Nordic Bioscience, Herlev, Denmark.

Peter Rossing (P)

Steno Diabetes Center Copenhagen, Gentofte, Denmark.
University of Copenhagen, Copenhagen, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH